6505--Aprepitant Capsules

The Department of Veterans Affairs National Acquisition Center is seeking a pharmaceutical contract for Aprepitant Capsules through Solicitation Number 36E79725R0029. The solicitation covers six line items for different dosages and package sizes of Aprepitant capsules (40mg, 80mg, and 125mg), with quantities ranging from 361 to 5,287 packs per line item. Offerors must submit pricing for a base year and four one-year option periods, with a 0.5% Cost Recovery Fee embedded in pricing and pricing limited to two decimal places. Key qualifications include providing a Letter of Commitment from the manufacturer, maintaining FDA current Good Manufacturing Practices (cGMP) status, and complying with Drug Supply Chain Security Act (DSCSA) requirements. The solicitation closes on April 10, 2025, at 2:30 PM CT, with an anticipated contract effective date of March 27, 2025.

The contract is not set aside for any specific designation, though it appears to be oriented toward small businesses with a size standard of 1,300 employees. The procurement will serve multiple federal agencies, including the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service. Pharmaceutical products will be distributed through Pharmaceutical Prime Vendor (PPV) programs, with offerors required to provide unique 11-digit National Drug Code (NDC) numbers for their products. While specific award values are not explicitly stated, the multi-year contract structure and broad agency participation suggest a potentially significant procurement opportunity. The contract's comprehensive approach covers multiple dosage strengths and package sizes, indicating a robust pharmaceutical supply strategy designed to meet diverse medical needs across federal healthcare systems.